
An independent advisory panel recommended accelerated FDA approval of Merck & Co's drug Isentress (raltegravir) for patients who have drug-resistant strains of HIV (Chong J-R. Los Angeles Times. September 6, 2007). If approved, Isentress would be the first in a new class of AIDS drugs, integrase inhibitors, that aim to prevent HIV from integrating into human DNA during the replication process.
